90 related articles for article (PubMed ID: 32053087)
1. Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro.
Silveira IC; Carneiro ACDM; Hiss LS; Crema VO
Anticancer Agents Med Chem; 2020; 20(6):751-755. PubMed ID: 32053087
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor TKI-258 inhibits cell motility in oral squamous cell carcinoma in vitro.
Carneiro ACDM; Silveira ICD; Rezende AS; Silva BRO; Crema VO
J Oral Pathol Med; 2017 Aug; 46(7):484-488. PubMed ID: 27732737
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
4. RhoA/ROCKs signaling is increased by treatment with TKI-258 and leads to increased apoptosis in SCC-4 oral squamous cell carcinoma cell line.
Carneiro ACDM; De Vito FB; Moraes-Souza H; Crema VO
J Oral Pathol Med; 2021 Apr; 50(4):394-402. PubMed ID: 33222274
[TBL] [Abstract][Full Text] [Related]
5. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
6. Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.
Brands RC; Knierim LM; De Donno F; Steinacker V; Hartmann S; Seher A; Kübler AC; Müller-Richter UDA
Oncol Rep; 2017 Sep; 38(3):1877-1885. PubMed ID: 28714017
[TBL] [Abstract][Full Text] [Related]
7. Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells.
Zainal NS; Gan CP; Lau BF; Yee PS; Tiong KH; Abdul Rahman ZA; Patel V; Cheong SC
Phytomedicine; 2018 Jan; 39():33-41. PubMed ID: 29433681
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
9. Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Iwase M; Yoshiba S; Uchid M; Takaoka S; Kurihara Y; Ito D; Hatori M; Shintani S
Int J Oncol; 2007 Nov; 31(5):1141-7. PubMed ID: 17912441
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line.
Qiu Y; Li C; Wang Q; Zeng X; Ji P
Cancer Med; 2018 Feb; 7(2):397-407. PubMed ID: 29316373
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
Hsu CM; Lin PM; Lin HC; Tsai YT; Tsai MS; Li SH; Wu CY; Yang YH; Lin SF; Yang MY
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30423811
[TBL] [Abstract][Full Text] [Related]
12. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
13. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
[TBL] [Abstract][Full Text] [Related]
14. Eldecalcitol (ED-71), an analog of 1α,25(OH)
Shintani T; Takatsu F; Rosli SNZ; Usui E; Hamada A; Sumi K; Hayashido Y; Toratani S; Okamoto T
In Vitro Cell Dev Biol Anim; 2017 Oct; 53(9):810-817. PubMed ID: 28710602
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.
Smolensky D; Rathore K; Bourn J; Cekanova M
J Cell Biochem; 2017 Sep; 118(9):2615-2624. PubMed ID: 27649518
[TBL] [Abstract][Full Text] [Related]
16. The Role of the LY294002 - A Non-Selective Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) Pathway- in Cell Survival and Proliferation in Cell Line SCC-25.
Duarte A; Silveira GG; Soave DF; Costa JPO; Silva AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3377-3383. PubMed ID: 31759362
[TBL] [Abstract][Full Text] [Related]
17. Effects of IGF-1 on Proliferation, Angiogenesis, Tumor Stem Cell Populations and Activation of AKT and Hedgehog Pathways in Oral Squamous Cell Carcinoma.
Ferreira Mendes JM; de Faro Valverde L; Torres Andion Vidal M; Paredes BD; Coelho P; Allahdadi KJ; Coletta RD; Souza BSF; Rocha CAG
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899449
[TBL] [Abstract][Full Text] [Related]
18. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.
Zhen L; Fan D; Yi X; Cao X; Chen D; Wang L
Int J Clin Exp Pathol; 2014; 7(10):6438-46. PubMed ID: 25400722
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits oral squamous cell carcinoma SCC-9 cells proliferation by regulating miR-9 expression.
Xiao C; Wang L; Zhu L; Zhang C; Zhou J
Biochem Biophys Res Commun; 2014 Nov; 454(4):576-80. PubMed ID: 25450696
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Aggarwal S; John S; Sapra L; Sharma SC; Das SN
Cancer Chemother Pharmacol; 2019 Mar; 83(3):451-461. PubMed ID: 30519710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
